MYOME, INC


Associated tags: CLIA, Clinical Laboratory, Doctor of Philosophy, PRS, Medical imaging, Polygene, Death, MD, Form W-9, Breast cancer, American Cancer Society, Odds ratio, Patient, Cancer, Research, Woman, Risk assessment, Society, Coronary artery disease, American Society of Human Genetics, CAD, Genetics

Locations: CALIFORNIA, DC, WASHINGTON

MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
PRS, ASHG, American Society of Human Genetics, CAD, NRI, Polygene, Genetics, Mortality, Coronary artery disease, Doctor of Philosophy, Society, Genetic epidemiology, Risk, Risk assessment, Human genetics, Moyamoya disease, PCE, Form W-9, ASCVD, CI, Pharmaceutical industry, MD

MENLO PARK, Calif., Nov. 2, 2023 /PRNewswire/ -- MyOme, Inc., a pioneering clinical whole genome platform analysis company specializing in polygenic risk scores, will present data during the 2023 American Society of Human Genetics (ASHG) Annual Meeting taking place from November 1-5, 2023 in Washington, DC. The focus will be on the integrated polygenic risk score, caIRS, which combines genetics with traditional clinical risk factors to improve the identification of high-risk individuals for coronary artery disease (CAD) across diverse populations.

Key Points: 
  • The focus will be on the integrated polygenic risk score, caIRS, which combines genetics with traditional clinical risk factors to improve the identification of high-risk individuals for coronary artery disease (CAD) across diverse populations.
  • Traditionally, most CAD risk assessment tools and tests have been validated on a relatively narrow population.
  • Polygenic risk scores (PRS), which aggregate millions of genetic variants of small effect size into a single score, offer the potential to improve the accuracy of clinical risk assessment tools.
  • MyOme has developed and validated an integrated risk score that combines a cross-ancestry PRS with the PCE (caIRS).

MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting

Retrieved on: 
Thursday, March 16, 2023
Polygene, Research, WGS, Mortality, CAD, Moyamoya disease, Cholesterol, ACMG, Risk, American College of Medical Genetics and Genomics, Death, DSM-IV codes, PCE, Patient, American College, CMA, SNV calling from NGS data, IRS, Diagnosis, Oxford Nanopore Technologies, ASCVD, Doctor of Philosophy, ONT, Coronary artery disease, CNV, Medical genetics, Whole genome sequencing, PRS, Medical imaging, Medical device, Genomics

MENLO PARK, Calif., March 16, 2023 /PRNewswire/ -- MyOme, Inc., a clinical whole genome platform analysis company and a leader in the development of polygenic risk scores with relevance across multiple ancestries, will share data from three presentations at the 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting being held March 14-18, 2023. Featured as one of only 20 "Rapid Fire" presentations is the development and validation of an integrated polygenic risk score that improved coronary artery disease prediction.

Key Points: 
  • Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical tool.
  • Featured as one of only 20 "Rapid Fire" presentations is the development and validation of an integrated polygenic risk score that improved coronary artery disease prediction.
  • Most tests and tools that assess risk for coronary artery disease (CAD), the leading global cause of death, have been validated on a narrow population.
  • To support diverse ancestries, MyOme developed and validated an integrated risk score (IRS) that combines a cross-ancestry PRS (caPRS) with ASCVD-PCE.

MyOme Announces Publication of a Validated Cross-Ancestry Polygenic Risk Score for Breast Cancer

Retrieved on: 
Wednesday, February 22, 2023
Cancer, Woman, Form W-9, JCO, CI, PRS, Breast cancer, Classification, Patient, American Cancer Society, SD, Research, Health, Death, Odds ratio, Risk, Disease, Risk assessment, Genome, Marker beacon, Doctor of Philosophy, Medical imaging, Birth control, Vaccine, Natera, MD

MENLO PARK, Calif., Feb. 22, 2023 /PRNewswire/ -- Myome, Inc., a clinical whole genome platform analysis company and a leader in the development of polygenic risk scores with relevance across multiple ancestries, today announced the publication in JCO Precision Oncology of a validation study for its cross-ancestry, integrated risk score. In the study, data from over 130,000 women demonstrated that MyOme's cross-ancestry, integrated risk score (caIRS) significantly improved breast cancer risk prediction over the common clinical measurement, Tyrer-Cuzick (T-C) alone.

Key Points: 
  • In the study, data from over 130,000 women demonstrated that MyOme's cross-ancestry, integrated risk score (caIRS) significantly improved breast cancer risk prediction over the common clinical measurement, Tyrer-Cuzick (T-C) alone.
  • To address this issue, MyOme has developed a cross-ancestry, integrated polygenic risk score (caIRS) for breast cancer.
  • The caIRS integrates hundreds of thousands of genetic markers across the genome to support sophisticated disease and ancestral models and combines a cross-ancestry polygenic risk score with a clinical estimator for breast cancer risk (T-C) to provide a more comprehensive risk assessment.
  • The authors of the study assessed the association between the caIRS and breast cancer risk in two validation cohorts of more than 130,000 women.

MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment

Retrieved on: 
Thursday, October 27, 2022
Society, Doctor of Philosophy, Odds ratio, Cancer, American Cancer Society, Risk assessment, Risk, Breast cancer, Human genetics, Form W-9, Death, Patient, Multimedia, Polygene, American Society of Human Genetics, ASHG, Woman, Clinical Laboratory, Population, CLIA, Genetics, Medicine, Birth control, Medical imaging, MD

MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ -- MyOme, a clinical whole genome platform analysis company, today announced new data on its cross-ancestry integrated risk score (caIRS) for breast cancer risk assessment that will be presented at the 2022 American Society of Human Genetics (ASHG) Annual Meeting in Los Angeles. In a study on more than 270,000 women across multiple ancestries, data showed that there was a significant increase in breast cancer risk assessment performance when a cross-ancestry polygenic risk score was integrated into the standard of care risk prediction tool.

Key Points: 
  • MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ -- MyOme , a clinical whole genome platform analysis company, today announced new data on its cross-ancestry integrated risk score (caIRS) for breast cancer risk assessment that will be presented at the 2022 American Society of Human Genetics (ASHG) Annual Meeting in Los Angeles.
  • In a study on more than 270,000 women across multiple ancestries, data showed that there was a significant increase in breast cancer risk assessment performance when a cross-ancestry polygenic risk score was integrated into the standard of care risk prediction tool.
  • Hispanic women showed the largest improvement in remaining lifetime breast cancer risk; 44% increase in odds ratio per unit standard deviation (increase from 1.31 to 1.88)
    "Commonly used breast cancer risk assessment tools based on clinical and family history are not well calibrated for women of certain ancestries.
  • Breast cancer is the most common cancer among women and a leading cause of cancer mortality.

MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast Cancer

Retrieved on: 
Wednesday, June 1, 2022
Woman, American Cancer Society, Death, Association, Clinical Laboratory, Research, Society, Doctor of Philosophy, Breast cancer, CLIA, ASCO, Polygene, Annual general meeting, Multimedia, American Society of Clinical Oncology, PRS, Risk, Odds ratio, Cancer, Medical imaging, MD

MENLO PARK, Calif., June 1, 2022 /PRNewswire/ -- MyOme, a clinical whole genome platform analysis company, today announced new data on a cross ancestry polygenic risk score (caPRS) for breast cancer that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Using a proprietary informatics approach to PRS that provides benefit across multiple ancestries, MyOme showed a significant association between their caPRS and breast cancer in a study including more than 130,000 women across multiple ancestries

Key Points: 
  • MENLO PARK, Calif., June 1, 2022 /PRNewswire/ -- MyOme , a clinical whole genome platform analysis company, today announced new data on a cross ancestry polygenic risk score (caPRS) for breast cancer that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Polygenic risk scores aggregate hundreds or potentially thousands of variants into a single measure of disease risk.
  • PRS has the potential to inform the 90-95% of women without rare breast cancer genetic mutations of their risk for breast cancer," said Akash Kumar, MD, PhD, chief medical officer of MyOme.
  • Breast cancer is the most common cancer among women and a leading cause of cancer mortality.